Lantern Pharma Q3 2024 earnings call held; no financial details in 8-K

Lantern Pharma Inc.

2024-Q3 EPS reported -$1.39

Conference call and live webinar occurred on November 7, 2024 for Q3 results.
Presentation covering financial and operating results furnished as Exhibit 99.1.
No specific revenue, EPS, or guidance figures were disclosed in this filing.

item 7.01 item 9.01

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-044124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.